Literature DB >> 26201641

Small intestinal bacterial overgrowth and delayed orocecal transit time in patients with cirrhosis and low-grade hepatic encephalopathy.

Manish Kumar Lunia1, Barjesh Chander Sharma2, Sanjeev Sachdeva1.   

Abstract

BACKGROUND: Hepatic encephalopathy (HE) is associated with poor prognosis in cirrhosis. Gut-derived nitrogenous substances play a role in pathogenesis of HE. The present study was conducted to assess small intestinal bacterial overgrowth (SIBO) and prolonged orocecal transit time (OCTT) in cirrhosis and low-grade HE.
METHODS: In cross-sectional prospective study, 75 patients were divided into 3 groups: group 1 (no HE, n = 31), group 2 (minimal HE, n = 29), and group 3 (early/grade 1 HE, n = 15). Minimal HE (MHE) was diagnosed when psychometric hepatic encephalopathy score (PHES) was ≤5. Early HE was diagnosed, according to West Haven criteria. All patients underwent glucose hydrogen breath test (GHBT) for SIBO and lactulose hydrogen breath test (LHBT) for OCTT.
RESULTS: A total of 29 patients (38.67 %) had MHE and 15 (20 %) had early HE. Prevalence of MHE in Child-Turcotte-Pugh (CTP) class A, B, and C was 33.3, 38.71, and 45 %, respectively, while SIBO was detected in 26 (34.67 %). Prevalence of SIBO was 12.5 % in CTP class A, 41.94 % in CTP class B, and 50 % in CTP class C. Five (16.13 %) patients in no HE group had SIBO as compared to 14 (48.28 %) in MHE group and 7 (46.67 %) in early HE group (p = 0.018). OCTT was 111.13 ± 13.95 min in patients with no HE as compared to 137.59 ± 14.80 min in patients with MHE and 150 ± 15.12 min in patients with early HE (p < 0.001). OCTT was significantly prolonged in patients with SIBO (145 ± 17.49 min) than in those without SIBO (120.71 ± 18.3 min) (p < 0.001).
CONCLUSION: SIBO and delayed OCTT are more common with MHE and early HE in patients with cirrhosis.

Entities:  

Keywords:  Cirrhosis; Hepatic encephalopathy; Orocecal Transit time; Small intestinal bacterial overgrowth

Year:  2012        PMID: 26201641     DOI: 10.1007/s12072-012-9360-9

Source DB:  PubMed          Journal:  Hepatol Int        ISSN: 1936-0533            Impact factor:   6.047


  28 in total

1.  Critical flicker frequency for quantification of low-grade hepatic encephalopathy.

Authors:  Gerald Kircheis; Matthias Wettstein; Lars Timmermann; Alfons Schnitzler; Dieter Häussinger
Journal:  Hepatology       Date:  2002-02       Impact factor: 17.425

Review 2.  Minimal hepatic encephalopathy: consensus statement of a working party of the Indian National Association for Study of the Liver.

Authors:  Radha K Dhiman; Vivek A Saraswat; Barjesh K Sharma; Shiv K Sarin; Yogesh K Chawla; Roger Butterworth; Ajay Duseja; Rakesh Aggarwal; Deepak Amarapurkar; Praveen Sharma; Kaushal Madan; Samir Shah; Avnish K Seth; Rakesh K Gupta; Abraham Koshy; Ramesh R Rai; Jang B Dilawari; Sri Prakash Mishra; Subrat K Acharya
Journal:  J Gastroenterol Hepatol       Date:  2010-06       Impact factor: 4.029

Review 3.  Review article: the burden of hepatic encephalopathy.

Authors:  F F Poordad
Journal:  Aliment Pharmacol Ther       Date:  2007-02       Impact factor: 8.171

4.  Autonomic neuropathy and chronic liver disease.

Authors:  P J Thuluvath; D R Triger
Journal:  Q J Med       Date:  1989-08

5.  Hepatic encephalopathy--definition, nomenclature, diagnosis, and quantification: final report of the working party at the 11th World Congresses of Gastroenterology, Vienna, 1998.

Authors:  Peter Ferenci; Alan Lockwood; Kevin Mullen; Ralph Tarter; Karin Weissenborn; Andres T Blei
Journal:  Hepatology       Date:  2002-03       Impact factor: 17.425

6.  Investigation of autonomic function and orocecal transit time in patients with nonalcoholic cirrhosis and the potential influence of these factors on disease outcome.

Authors:  Cristiane Kibune Nagasako; Márcio Jansen de Oliveira Figueiredo; Jazon Romilson de Souza Almeida; Sônia Letícia Silva Lorena; Helena Midori Akasaka; Célia Regina Pavan; Ademar Yamanaka; Tiago Sevá Pereira; Elza Cotrim Soares; Maria Aparecida Mesquita
Journal:  J Clin Gastroenterol       Date:  2009-10       Impact factor: 3.062

7.  Probiotic yogurt for the treatment of minimal hepatic encephalopathy.

Authors:  Jasmohan S Bajaj; Kia Saeian; Kenneth M Christensen; Muhammad Hafeezullah; Rajiv R Varma; Jose Franco; Joan A Pleuss; Glenn Krakower; Raymond G Hoffmann; David G Binion
Journal:  Am J Gastroenterol       Date:  2008-07       Impact factor: 10.864

8.  Frequency and factors associated with small intestinal bacterial overgrowth in patients with cirrhosis of the liver and extra hepatic portal venous obstruction.

Authors:  C P Lakshmi; Uday C Ghoshal; Sunil Kumar; Amit Goel; Asha Misra; Samir Mohindra; G Choudhuri
Journal:  Dig Dis Sci       Date:  2009-05-08       Impact factor: 3.199

9.  Small intestinal bacterial overgrowth in human cirrhosis is associated with systemic endotoxemia.

Authors:  Tilman M Bauer; Henning Schwacha; Bernhard Steinbrückner; Folke E Brinkmann; Anette K Ditzen; John J Aponte; Klaus Pelz; Dieter Berger; Manfred Kist; Hubert E Blum
Journal:  Am J Gastroenterol       Date:  2002-09       Impact factor: 10.864

10.  Synbiotic modulation of gut flora: effect on minimal hepatic encephalopathy in patients with cirrhosis.

Authors:  Qing Liu; Zhong Ping Duan; Da Kang Ha; Stig Bengmark; Jelica Kurtovic; Stephen M Riordan
Journal:  Hepatology       Date:  2004-05       Impact factor: 17.425

View more
  10 in total

Review 1.  Gut microbiota: its role in hepatic encephalopathy.

Authors:  Rahul Rai; Vivek A Saraswat; Radha K Dhiman
Journal:  J Clin Exp Hepatol       Date:  2014-12-16

Review 2.  Probiotics in management of hepatic encephalopathy.

Authors:  Barjesh Chander Sharma; Jatinderpal Singh
Journal:  Metab Brain Dis       Date:  2016-04-28       Impact factor: 3.584

Review 3.  Small Intestinal Bacterial Overgrowth in Patients With Cirrhosis.

Authors:  Gaurav Ghosh; Arun B Jesudian
Journal:  J Clin Exp Hepatol       Date:  2018-08-27

4.  Small intestinal bacterial overgrowth in cirrhosis: systematic review and meta-analysis.

Authors:  Roman Maslennikov; Chavdar Pavlov; Vladimir Ivashkin
Journal:  Hepatol Int       Date:  2018-10-04       Impact factor: 6.047

Review 5.  Irritable bowel syndrome and small intestinal bacterial overgrowth: meaningful association or unnecessary hype.

Authors:  Uday C Ghoshal; Deepakshi Srivastava
Journal:  World J Gastroenterol       Date:  2014-03-14       Impact factor: 5.742

Review 6.  Dietary approach and gut microbiota modulation for chronic hepatic encephalopathy in cirrhosis.

Authors:  Daniela Campion; Ilaria Giovo; Paola Ponzo; Giorgio M Saracco; Federico Balzola; Carlo Alessandria
Journal:  World J Hepatol       Date:  2019-06-27

Review 7.  Gut Microbiota Modulation and Fecal Transplantation: An Overview on Innovative Strategies for Hepatic Encephalopathy Treatment.

Authors:  Ramzi Hassouneh; Jasmohan S Bajaj
Journal:  J Clin Med       Date:  2021-01-18       Impact factor: 4.241

8.  Gut dysbiosis and small intestinal bacterial overgrowth as independent forms of gut microbiota disorders in cirrhosis.

Authors:  Roman Maslennikov; Vladimir Ivashkin; Irina Efremova; Elena Poluektova; Anna Kudryavtseva; George Krasnov
Journal:  World J Gastroenterol       Date:  2022-03-14       Impact factor: 5.742

9.  Asian-Pacific consensus on small intestinal bacterial overgrowth in gastrointestinal disorders: An initiative of the Indian Neurogastroenterology and Motility Association.

Authors:  Uday C Ghoshal; Sanjeev Sachdeva; Ujjala Ghoshal; Asha Misra; Amarender Singh Puri; Nitesh Pratap; Ayesha Shah; M Masudur Rahman; Kok Ann Gwee; Victoria P Y Tan; Tahmeed Ahmed; Yeong Yeh Lee; B S Ramakrishna; Rupjyoti Talukdar; S V Rana; Saroj K Sinha; Minhu Chen; Nayoung Kim; Gerald Holtmann
Journal:  Indian J Gastroenterol       Date:  2022-10-10

Review 10.  Current approach to treatment of minimal hepatic encephalopathy in patients with liver cirrhosis.

Authors:  Segundo Moran; Marlene López-Sánchez; María Del Pilar Milke-García; Gustavo Rodríguez-Leal
Journal:  World J Gastroenterol       Date:  2021-06-14       Impact factor: 5.742

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.